Tetrabenazine, a VMAT-2 enzyme inhibitor, is used to treat sudden movements caused by neurodegenerative diseases called Huntington's disease and tardive dyskinesia, which are uncontrollable by the individual. The extent to which this drug inhibits the release of the monoamines noradrenaline, dopamine, and serotonin in different brain areas is not yet known. This is what a collaboration between the Sperlágh group and researchers at Richter Gedeon Nyrt led by Szilveszter E. Vizi investigated. The significance of the result is underlined by the fact that the work, first submitted by Pál Tod and with corresponding authorship by Professor Vizi, was published in the leading international journal of pharmacology.

"Autumn is here, it's here again", we could have said with Petőfi, and we could have agreed with the rest, that autumn is beautiful. The first day of our stay in Várgestes, 26 September, was so beautiful that you couldn't wish for a more beautiful day since the end of September. The main reason for our satisfaction, however, was that our Institute conference went very well!

The HUN-REN KOKI and the Weizmann Institute in Israel co-organised a two-day symposium at the KOKI, 28-29 October 2024, which contributed to the promotion of long-term joint neuroscience research between Hungary and Israel.

Copenhagen not only provided an excellent venue, but also a wonderful summer weather during the last week of August for the 2500 participants of EMC204, the largest meeting of microscopists in Europe. The Hungarian Microscopy Society was represented by Techoorg Linda and eight microscopists, including four colleagues from KOKI.